

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/212191 A1

(51) International Patent Classification:

A61K 31/58 (2006.01) A61K 9/00 (2006.01)
A61K 31/7034 (2006.01) A61K 9/12 (2006.01)
A61P 11/06 (2006.01) A61K 47/24 (2006.01)

(21) International Application Number:

PCT/US2023/020200

(22) International Filing Date:

27 April 2023 (27.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/363,767 28 April 2022 (28.04.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85,
SE-151 85 Sodertalje (SE).

(72) Inventor; and

(71) Applicant (for EG only): **CAPPELLETTI, Christy**
[US/US]; 4222 Emperor Blvd, Suite 560, Durham, North
Carolina 27703 (US).

(72) Inventors: **JOHANSSON, Eva**; Pepparedsleden 1, SE-431
83 Molndal (SE). **COOPER, Mark**; AstraZeneca UK Lim-
ited, 1 Francis Crick Ave., Cambridge Biomedical Cam-
pus, Cambridge CB2 0AA (GB). **FENBY, Benjamin**; As-
traZeneca UK Limited, 1 Francis Crick Ave., Cambridge
Biomedical Campus, Cambridge CB2 0AA (GB). **MAES,**
Andrea; AstraZeneca Pharmaceuticals LP, 1800 Concord
Pike, Wilmington, Delaware 19850 (US). **REILLY, Lau-**
rence; Bond Avillion 2 Development LP, Sarnia House, Le
Truchot, St. Peter Port, GY1 1GR (GG). **REES, Robert**;
Bond Avillion 2 Development LP, Sarnia House, Le Tru-
chot, St. Peter Port, GY1 1GR (GG). **RIMMER, Martin**;

(54) Title: COMBINATION OF ALBUTEROL AND BUDESONIDE FOR THE TREATMENT OF ASTHMA




FIG. 2

(57) Abstract: The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and/or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and/or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality

[Continued on next page]

Bond Avillion 2 Development LP, Sarnia House, Le Truchot, St. Peter Port, GY1 1GR (GG).

(74) **Agent:** **RAO, Minxi** et al.; MEDLER FERRO WOODHOUSE & MILLS PLLC, 8201 Greensboro Drive, Suite 1060, McLean, Virginia 22102 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

of respirable suspending particles.